Retrophin Inc. (RTRX) Stake Raised by Swiss National Bank
Swiss National Bank boosted its position in Retrophin Inc. (NASDAQ:RTRX) by 12.6% during the second quarter, Holdings Channel reports. The firm owned 56,200 shares of the biopharmaceutical company’s stock after buying an additional 6,300 shares during the period. Swiss National Bank owned approximately 0.15% of Retrophin worth $1,001,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently bought and sold shares of RTRX. Scopia Capital Management LP raised its stake in Retrophin by 874.8% in the first quarter. Scopia Capital Management LP now owns 3,598,222 shares of the biopharmaceutical company’s stock worth $49,152,000 after buying an additional 3,229,087 shares during the period. BlackRock Fund Advisors raised its stake in Retrophin by 1.8% in the first quarter. BlackRock Fund Advisors now owns 1,302,989 shares of the biopharmaceutical company’s stock worth $17,799,000 after buying an additional 22,903 shares during the period. Spark Investment Management LLC raised its stake in Retrophin by 64.2% in the first quarter. Spark Investment Management LLC now owns 393,300 shares of the biopharmaceutical company’s stock worth $5,372,000 after buying an additional 153,800 shares during the period. Geode Capital Management LLC raised its stake in Retrophin by 9.7% in the first quarter. Geode Capital Management LLC now owns 262,729 shares of the biopharmaceutical company’s stock worth $3,588,000 after buying an additional 23,275 shares during the period. Finally, Teachers Advisors Inc. raised its stake in Retrophin by 14.3% in the first quarter. Teachers Advisors Inc. now owns 231,492 shares of the biopharmaceutical company’s stock worth $3,162,000 after buying an additional 28,956 shares during the period.
Retrophin Inc. (NASDAQ:RTRX) traded up 1.36% during trading on Wednesday, hitting $23.09. 176,091 shares of the stock were exchanged. The stock’s 50 day moving average price is $20.06 and its 200 day moving average price is $17.43. The stock has a market cap of $848.12 million, a P/E ratio of 9.38 and a beta of 1.02. Retrophin Inc. has a 12 month low of $11.60 and a 12 month high of $24.57.
Retrophin (NASDAQ:RTRX) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.30. The firm had revenue of $33.30 million for the quarter, compared to analysts’ expectations of $32.73 million. Retrophin had a net margin of 83.57% and a negative return on equity of 0.52%. The firm’s revenue for the quarter was up 38.2% on a year-over-year basis. Analysts forecast that Retrophin Inc. will post $0.09 EPS for the current fiscal year.
A number of equities analysts have recently commented on the stock. JMP Securities reaffirmed a “buy” rating on shares of Retrophin in a research report on Saturday, July 9th. Zacks Investment Research lowered shares of Retrophin from a “buy” rating to a “hold” rating in a research report on Tuesday, August 2nd. Leerink Swann reaffirmed a “buy” rating and set a $27.00 target price on shares of Retrophin in a research report on Monday, June 27th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $28.00 target price (up from $25.00) on shares of Retrophin in a research report on Monday, August 8th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $27.60.
In other Retrophin news, EVP Alvin Shih sold 8,750 shares of Retrophin stock in a transaction that occurred on Thursday, September 1st. The shares were sold at an average price of $16.24, for a total transaction of $142,100.00. Following the transaction, the executive vice president now directly owns 158,334 shares of the company’s stock, valued at $2,571,344.16. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 2.41% of the company’s stock.
Retrophin Company Profile
Retrophin, Inc is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.
Want to see what other hedge funds are holding RTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Retrophin Inc. (NASDAQ:RTRX).
Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with MarketBeat.com's FREE daily email newsletter.